BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Biochemistry - Immunology

Modest Elevation in BNP in Asymptomatic Hypertensive Patients Reflects Sub-Clinical Cardiac Remodeling, Inflammation and Extracellular Matrix Changes
Published: Monday, November 12, 2012
Author: Dermot Phelan et al.

by Dermot Phelan, Chris Watson, Ramon Martos, Patrick Collier, Anil Patle, Seamas Donnelly, Mark Ledwidge, John Baugh, Ken McDonald

In asymptomatic subjects B-type natriuretic peptide (BNP) is associated with adverse cardiovascular outcomes even at levels well below contemporary thresholds used for the diagnosis of heart failure. The mechanisms behind these observations are unclear. We examined the hypothesis that in an asymptomatic hypertensive population BNP would be associated with sub-clinical evidence of cardiac remodeling, inflammation and extracellular matrix (ECM) alterations. We performed transthoracic echocardiography and sampled coronary sinus (CS) and peripheral serum from patients with low (n?=?14) and high BNP (n?=?27). Peripheral BNP was closely associated with CS levels (r?=?0.92, p<0.001). CS BNP correlated significantly with CS levels of markers of collagen type I and III turnover including: PINP (r?=?0.44, p?=?0.008), CITP (r?=?0.35, p?=?0.03) and PIIINP (r?=?0.35, p?=?0.001), and with CS levels of inflammatory cytokines including: TNF-a (r?=?0.49, p?=?0.002), IL-6 (r?=?0.35, p?=?0.04), and IL-8 (r?=?0.54, p<0.001). The high BNP group had greater CS expression of fibro-inflammatory biomarkers including: CITP (3.8±0.7 versus 5.1±1.9, p?=?0.007), TNF-a (3.2±0.5 versus 3.7±1.1, p?=?003), IL-6 (1.9±1.3 versus 3.4±2.7, p?=?0.02) and hsCRP (1.2±1.1 versus 2.4±1.1, p?=?0.04), and greater left ventricular mass index (97±20 versus 118±26 g/m2, p?=?0.03) and left atrial volume index (18±2 versus 21±4, p?=?0.008). Our data provide insight into the mechanisms behind the observed negative prognostic impact of modest elevations in BNP and suggest that in an asymptomatic hypertensive cohort a peripheral BNP measurement may be a useful marker of an early, sub-clinical pathological process characterized by cardiac remodeling, inflammation and ECM alterations.